Skip to content

Earnings yield at other companies

Pfizer logo
PfizerPFE
6.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.4%-1.1pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
5%+2.6pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
15.4%+10.2pp
Insmed logo
InsmedINSM
-3.4%-1.2pp
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-6.6%-2.1pp

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.82B-63.1%
Enterprise value$1.56B-67.2%
P/S0.8×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s earnings yield?
Sarepta Therapeutics, Inc. (SRPT) reported earnings yield of -4% in Q1 2025.
How has Sarepta Therapeutics, Inc.'s earnings yield changed year-over-year?
Sarepta Therapeutics, Inc.'s earnings yield decreased by 1597.5% year-over-year, from -0.2% to -4%.
What is the long-term trend for Sarepta Therapeutics, Inc.'s earnings yield?
Over 4 years (2020 to 2024), Sarepta Therapeutics, Inc.'s earnings yield has grown at a -16.1% compound annual growth rate (CAGR), from -4.1% to 2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.